You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameRisedronate
Accession NumberDB00884  (APRD00410, DB02782)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionRisedronate is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone.
Structure
Thumb
Synonyms
Acide risédroniqe
Acido risedronico
Acidum risedronicum
Ridron
Risedronate
Risedronic acid
Risedronsäure
External Identifiers
  • NE-58095
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actoneltablet30 mgoralWarner Chilcott Canada Co1999-09-07Not applicableCanada
Actoneltablet, film coated30 mg/1oralWarner Chilcott Pharmaceuticals Inc.1998-03-27Not applicableUs
Actoneltablet150 mgoralWarner Chilcott Canada Co2008-12-01Not applicableCanada
Actoneltablet75 mgoralWarner Chilcott Canada Co2007-08-132016-08-05Canada
Actoneltablet, film coated5 mg/1oralPhysicians Total Care, Inc.2002-03-15Not applicableUs
Actoneltablet5 mgoralWarner Chilcott Canada Co2000-07-25Not applicableCanada
Actoneltablet, film coated5 mg/1oralWarner Chilcott Pharmaceuticals Inc.2000-04-14Not applicableUs
Actoneltablet, film coated35 mg/1oralPhysicians Total Care, Inc.2002-09-16Not applicableUs
Actoneltablet35 mgoralWarner Chilcott Canada Co2002-12-10Not applicableCanada
Actoneltablet, film coated35 mg/1oralWarner Chilcott Pharmaceuticals Inc.2002-05-17Not applicableUs
Actoneltablet, film coated150 mg/1oralPhysicians Total Care, Inc.2009-10-05Not applicableUs
Actoneltablet, film coated150 mg/1oralWarner Chilcott Pharmaceuticals Inc.2008-04-22Not applicableUs
Actonel Drtablet (delayed-release)35 mgoralWarner Chilcott Canada Co2011-08-10Not applicableCanada
Auro-risedronatetablet5 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-risedronatetablet30 mgoralAuro Pharma IncNot applicableNot applicableCanada
Auro-risedronatetablet150 mgoralAuro Pharma Inc2016-04-13Not applicableCanada
Auro-risedronatetablet35 mgoralAuro Pharma Inc2013-07-08Not applicableCanada
Dom-risedronatetablet35 mgoralDominion Pharmacal2011-04-19Not applicableCanada
Jamp-risedronatetablet35 mgoralJamp Pharma Corporation2011-10-04Not applicableCanada
Mylan-risedronatetablet35 mgoralMylan Pharmaceuticals Ulc2011-06-16Not applicableCanada
Mylan-risedronatetablet150 mgoralMylan Pharmaceuticals Ulc2013-09-30Not applicableCanada
Ntp-risedronatetablet30 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-risedronatetablet35 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Ntp-risedronatetablet5 mgoralNt Pharma Canada LtdNot applicableNot applicableCanada
Pendo-risedronatetablet35 mgoralPendopharm Division Of De Pharmascience IncNot applicableNot applicableCanada
PHL-risedronatetablet35 mgoralPharmel IncNot applicableNot applicableCanada
PMS-risedronatetablet150 mgoralPharmascience Inc2014-05-28Not applicableCanada
PMS-risedronatetablet35 mgoralPharmascience Inc2010-07-27Not applicableCanada
Q-risedronatetablet35 mgoralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Ratio-risedronatetablet35 mgoralRatiopharm Inc Division Of Teva Canada Limited2010-07-272015-10-26Canada
Risedronatetablet35 mgoralSanis Health Inc2011-10-18Not applicableCanada
Risedronatetablet35 mgoralSivem Pharmaceuticals Ulc2011-04-08Not applicableCanada
Risedronatetablet5 mgoralSanis Health IncNot applicableNot applicableCanada
Risedronatetablet30 mgoralSanis Health IncNot applicableNot applicableCanada
Risedronatetablet35 mgoralPro Doc Limitee2010-10-15Not applicableCanada
Risedronate-35tablet35 mgoralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
Riva-risedronatetablet35 mgoralLaboratoire Riva Inc2010-07-28Not applicableCanada
Sandoz Risedronatetablet35 mgoralSandoz Canada Incorporated2010-07-28Not applicableCanada
Teva-risedronatetablet30 mgoralTeva Canada Limited2010-01-27Not applicableCanada
Teva-risedronatetablet35 mgoralTeva Canada Limited2010-01-27Not applicableCanada
Teva-risedronatetablet150 mgoralTeva Canada Limited2013-10-10Not applicableCanada
Teva-risedronatetablet5 mgoralTeva Canada Limited2010-01-27Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-risedronatetablet35 mgoralApotex Inc2010-11-10Not applicableCanada
Apo-risedronatetablet150 mgoralApotex Inc2012-05-17Not applicableCanada
Risedronate Sodiumtablet, film coated35 mg/1oralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated150 mg/1oralApotex Corp.2014-06-11Not applicableUs
Risedronate Sodiumtablet, film coated35 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate Sodiumtablet, film coated150 mg/1oralSun Pharma Global FZE2014-06-11Not applicableUs
Risedronate Sodiumtablet, film coated5 mg/1oralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated75 mg/1oralMylan Pharmaceuticals Inc.2014-06-102016-01-07Us
Risedronate Sodiumtablet, film coated35 mg/1oralApotex Corp.2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate Sodiumtablet, film coated5 mg/1oralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated30 mg/1oralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated5 mg/1oralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
Risedronate Sodiumtablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2015-06-01Not applicableUs
Risedronate Sodiumtablet, film coated30 mg/1oralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated35 mg/1oralSun Pharma Global FZE2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated75 mg/1oralApotex Corp.2014-06-11Not applicableUs
Risedronate Sodiumtablet, film coated150 mg/1oralMylan Pharmaceuticals Inc.2014-06-10Not applicableUs
Risedronate Sodiumtablet, film coated30 mg/1oralMacleods Pharmaceuticals Limited2015-12-09Not applicableUs
Risedronate Sodiumtablet, delayed release35 mg/1oralTeva Pharmaceuticals USA Inc2015-05-18Not applicableUs
Risedronate Sodiumtablet, film coated35 mg/1oralAurobindo Pharma Limited2015-11-30Not applicableUs
Risedronate Sodiumtablet, film coated75 mg/1oralSun Pharma Global FZE2014-06-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BenetTakeda
Brand mixtures
NameLabellerIngredients
ActonelWarner Chilcott (US), LLC
Actonel Plus CalciumWarner Chilcott Canada Co
Actonel Sachet KitWarner Chilcott Canada Co
AtelviaWarner Chilcott (US), LLC
PMS-risedronate Plus CalciumPharmascience Inc
Risedronate SodiumActavis Pharma, Inc.
Salts
Name/CASStructureProperties
Risedronate sodium
Thumb
  • InChI Key: DRFDPXKCEWYIAW-UHFFFAOYNA-M
  • Monoisotopic Mass: 304.983019378
  • Average Mass: 305.0941
DBSALT000494
Risedronate sodium hemi-pentahydrate
ThumbNot applicableDBSALT001515
Risedronate sodium monohydrate
ThumbNot applicableDBSALT001516
Categories
UNIIKM2Z91756Z
CAS number105462-24-6
WeightAverage: 283.1123
Monoisotopic: 283.001074735
Chemical FormulaC7H11NO7P2
InChI KeyInChIKey=IIDJRNMFWXDHID-UHFFFAOYSA-N
InChI
InChI=1S/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)
IUPAC Name
[1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl]phosphonic acid
SMILES
OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.
KingdomOrganic compounds
Super ClassOrganophosphorus compounds
ClassOrganic phosphonic acids and derivatives
Sub ClassBisphosphonates
Direct ParentBisphosphonates
Alternative Parents
Substituents
  • Bisphosphonate
  • Pyridine
  • Heteroaromatic compound
  • Organophosphonic acid
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of Paget's disease of the bone (osteitis deformans), postmenopausal and glucocorticoid-induced osteoporosis
PharmacodynamicsRisedronate is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism and is indicated for the treatment and prevention of osteoporosis in postmenopausal women.
Mechanism of actionThe action of risedronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Risedronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
Related Articles
AbsorptionRapid absorption (~1 hr) after an oral dose, occurs throughout the upper gastrointestinal tract
Volume of distribution
  • 13.8 L/kg
Protein binding~24%
Metabolism

No evidence found for metabolization of risedronate in humans or mammals

Route of eliminationRisedronate is excreted unchanged primarily via the kidney. Insignificant amounts (<0.1% of intravenous dose) of drug are excreted in the bile in rats.
Half life1.5 hours
Clearance
  • 122 mL/min
  • 73 mL/min [osteopenic postmenopausal women]
ToxicitySide effects include abdominal pain, anxiety, back pain, belching, bladder irritation, bone disorders and pain, bronchitis, bursitis, cataracts, chest pain, colitis, constipation, depression, diarrhea, difficulty breathing, dizziness, dry eyes, eye infection, flu-like symptoms, gas, headache, high blood pressure, infection, insomnia, itching, joint disorders and pain, leg cramps, muscle pain, muscle weakness, nausea, neck pain, nerve pain, pain, pneumonia, rash, ringing in ears, sinus problems, sore throat, stomach bleeding, stuffy or runny nose, swelling, tendon problems, tumor, ulcers, urinary tract infection, vertigo, vision problems, and weakness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Risedronate Action PathwayDrug actionSMP00112
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9357
Blood Brain Barrier+0.9172
Caco-2 permeable-0.6795
P-glycoprotein substrateNon-substrate0.6846
P-glycoprotein inhibitor INon-inhibitor0.9582
P-glycoprotein inhibitor IINon-inhibitor1.0
Renal organic cation transporterNon-inhibitor0.9542
CYP450 2C9 substrateNon-substrate0.8452
CYP450 2D6 substrateNon-substrate0.8162
CYP450 3A4 substrateNon-substrate0.7208
CYP450 1A2 substrateNon-inhibitor0.8778
CYP450 2C9 inhibitorNon-inhibitor0.8792
CYP450 2D6 inhibitorNon-inhibitor0.9062
CYP450 2C19 inhibitorNon-inhibitor0.8777
CYP450 3A4 inhibitorNon-inhibitor0.9068
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.989
Ames testNon AMES toxic0.7663
CarcinogenicityNon-carcinogens0.8386
BiodegradationNot ready biodegradable0.5058
Rat acute toxicity2.1053 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9095
hERG inhibition (predictor II)Non-inhibitor0.9303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Warner chilcott co llc
  • Teva pharmaceuticals usa
  • Procter & Gamble
Packagers
Dosage forms
FormRouteStrength
Tabletoral150 mg
Tabletoral30 mg
Tabletoral35 mg
Tabletoral5 mg
Tabletoral75 mg
Tablet, film coatedoral150 mg/1
Tablet (delayed-release)oral35 mg
Granules (effervescents); kit; tabletoral
Tablet, delayed releaseoral
Tabletoral
Tablet, delayed releaseoral35 mg/1
Tablet, film coatedoral
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral35 mg/1
Tablet, film coatedoral5 mg/1
Tablet, film coatedoral75 mg/1
Prices
Unit descriptionCostUnit
Actonel 150 mg tablet125.1USD tablet
Actonel 4 35 mg tablet Disp Pack119.43USD disp
Actonel 75 mg tablet54.83USD tablet
Actonel 30 mg tablet29.32USD tablet
Actonel 35 mg tablet28.75USD tablet
Actonel 5 mg tablet4.13USD tablet
Actonel with calcium tablet3.92USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2294595 No2001-08-212018-07-17Canada
CA2399976 No2007-03-272021-02-01Canada
US5994329 Yes1999-01-172019-01-17Us
US6015801 Yes1999-01-172019-01-17Us
US6096342 No1994-11-222011-11-22Us
US6165513 Yes1998-12-102018-12-10Us
US6432932 Yes1999-01-172019-01-17Us
US6465443 Yes1999-02-142019-02-14Us
US7192938 Yes2003-11-062023-11-06Us
US7645459 No2008-01-092028-01-09Us
US7645460 No2008-01-092028-01-09Us
US7718634 Yes2003-11-062023-11-06Us
US8246989 No2006-01-162026-01-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility10.4 mg/mLALOGPS
logP-0.75ALOGPS
logP-3.3ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)0.68ChemAxon
pKa (Strongest Basic)4.91ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area148.18 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity57.12 m3·mol-1ChemAxon
Polarizability21.91 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Srinivasa Rao V.N Divvela, Lenin Racha, Sivakumaran Meenakshisunderam, Ramesh Dandala, “Process for the preparation of risedronate sodium hemi-pentahydrate.” U.S. Patent US20070173484, issued July 26, 2007.

US20070173484
General ReferencesNot Available
External Links
ATC CodesM05BB02M05BA07M05BB04M05BB07
AHFS Codes
  • 92:00.00
PDB Entries
FDA labelDownload (1.52 MB)
MSDSDownload (57 KB)
Interactions
Drug Interactions
Drug
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Risedronate.
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Risedronate.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Risedronate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Risedronate.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Risedronate.
AlfuzosinAlfuzosin may increase the hypotensive activities of Risedronate.
Aluminum hydroxideThe serum concentration of Risedronate can be decreased when it is combined with Aluminum hydroxide.
Aluminum phosphateThe serum concentration of Risedronate can be decreased when it is combined with Aluminum phosphate.
AmikacinAmikacin may increase the hypocalcemic activities of Risedronate.
AmobarbitalThe metabolism of Risedronate can be increased when combined with Amobarbital.
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Risedronate.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Risedronate.
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Risedronate.
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Risedronate.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Risedronate.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Risedronate.
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Risedronate.
AsenapineThe serum concentration of Risedronate can be increased when it is combined with Asenapine.
AtosibanThe risk or severity of adverse effects can be increased when Risedronate is combined with Atosiban.
Atracurium besylateRisedronate may increase the neuromuscular blocking activities of Atracurium besylate.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Risedronate.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Risedronate.
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Risedronate.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Risedronate.
BarbitalThe metabolism of Risedronate can be increased when combined with Barbital.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Risedronate.
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Risedronate.
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Risedronate.
Bismuth SubcitrateThe serum concentration of Risedronate can be decreased when it is combined with Bismuth Subcitrate.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Risedronate.
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Risedronate.
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Risedronate.
Calcium carbonateThe serum concentration of Risedronate can be decreased when it is combined with Calcium carbonate.
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Risedronate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Risedronate.
CarvedilolCarvedilol may increase the hypotensive activities of Risedronate.
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Risedronate.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Risedronate.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Risedronate.
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Risedronate.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Risedronate.
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Risedronate.
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Risedronate.
CimetidineThe serum concentration of Risedronate can be increased when it is combined with Cimetidine.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Risedronate.
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Risedronate.
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Risedronate.
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Risedronate.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Risedronate.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Risedronate.
DaunorubicinDaunorubicin may increase the hypocalcemic activities of Risedronate.
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Risedronate.
DeferasiroxThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Risedronate.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Risedronate.
DihydrostreptomycinDihydrostreptomycin may increase the hypocalcemic activities of Risedronate.
DoxazosinDoxazosin may increase the hypotensive activities of Risedronate.
DoxepinThe serum concentration of Risedronate can be increased when it is combined with Doxepin.
DoxorubicinDoxorubicin may increase the hypocalcemic activities of Risedronate.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Risedronate.
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Risedronate.
EfavirenzThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Risedronate.
EpinastineThe serum concentration of Risedronate can be increased when it is combined with Epinastine.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Risedronate.
EpirubicinEpirubicin may increase the hypocalcemic activities of Risedronate.
EsomeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Esomeprazole.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Risedronate.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Risedronate.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Risedronate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Risedronate.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Risedronate.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Risedronate.
FamotidineThe serum concentration of Risedronate can be increased when it is combined with Famotidine.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Risedronate.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Risedronate.
Ferric CitrateThe serum concentration of Risedronate can be decreased when it is combined with Ferric Citrate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Risedronate.
FluconazoleThe serum concentration of Risedronate can be increased when it is combined with Fluconazole.
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Risedronate.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Risedronate.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Risedronate.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Risedronate.
FramycetinFramycetin may increase the hypocalcemic activities of Risedronate.
GentamicinGentamicin may increase the hypocalcemic activities of Risedronate.
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Risedronate.
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Risedronate.
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Risedronate.
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Risedronate.
HexobarbitalThe metabolism of Risedronate can be increased when combined with Hexobarbital.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Risedronate.
Hygromycin BHygromycin B may increase the hypocalcemic activities of Risedronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Risedronate.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Risedronate.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Risedronate.
IdarubicinIdarubicin may increase the hypocalcemic activities of Risedronate.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Risedronate.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Risedronate.
IndoraminIndoramin may increase the hypotensive activities of Risedronate.
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Risedronate.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Risedronate.
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Risedronate.
KanamycinKanamycin may increase the hypocalcemic activities of Risedronate.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Risedronate.
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronate.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Risedronate.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.
LabetalolLabetalol may increase the hypotensive activities of Risedronate.
LansoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Lansoprazole.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Risedronate.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Risedronate.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Risedronate.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Risedronate.
Magnesium carbonateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium carbonate.
Magnesium hydroxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium hydroxide.
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Risedronate is combined with Magnesium hydroxide.
Magnesium oxideThe serum concentration of Risedronate can be decreased when it is combined with Magnesium oxide.
Magnesium oxideThe risk or severity of adverse effects can be increased when Risedronate is combined with Magnesium oxide.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Risedronate.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Risedronate is combined with Magnesium Sulfate.
Magnesium SulfateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Sulfate.
Magnesium TrisilicateThe serum concentration of Risedronate can be decreased when it is combined with Magnesium Trisilicate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Risedronate.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Risedronate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Risedronate.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Risedronate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Risedronate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.
MethanthelineThe serum concentration of Risedronate can be increased when it is combined with Methantheline.
MethohexitalThe metabolism of Risedronate can be increased when combined with Methohexital.
MethylphenobarbitalThe metabolism of Risedronate can be increased when combined with Methylphenobarbital.
MetiamideThe serum concentration of Risedronate can be increased when it is combined with Metiamide.
MetrizamideMetrizamide may increase the hypocalcemic activities of Risedronate.
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Risedronate.
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Risedronate.
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Risedronate.
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Risedronate.
MivacuriumRisedronate may increase the neuromuscular blocking activities of Mivacurium.
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Risedronate.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Risedronate.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Risedronate.
NafcillinThe metabolism of Risedronate can be increased when combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Risedronate.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Risedronate.
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Risedronate.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Risedronate.
NeomycinNeomycin may increase the hypocalcemic activities of Risedronate.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Risedronate.
NetilmicinNetilmicin may increase the hypocalcemic activities of Risedronate.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Risedronate.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Risedronate.
NitroprussideRisedronate may increase the hypotensive activities of Nitroprusside.
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Risedronate.
NizatidineThe serum concentration of Risedronate can be increased when it is combined with Nizatidine.
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Risedronate.
OlanzapineThe serum concentration of Risedronate can be increased when it is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Risedronate.
OmeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Risedronate.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Risedronate.
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Risedronate.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Risedronate.
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Risedronate.
PantoprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Risedronate.
ParomomycinParomomycin may increase the hypocalcemic activities of Risedronate.
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Risedronate.
PentobarbitalThe metabolism of Risedronate can be increased when combined with Pentobarbital.
PhenobarbitalThe metabolism of Risedronate can be increased when combined with Phenobarbital.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Risedronate.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Risedronate.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Risedronate.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Risedronate.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Risedronate.
PlicamycinPlicamycin may increase the hypocalcemic activities of Risedronate.
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Risedronate.
PrazosinPrazosin may increase the hypotensive activities of Risedronate.
PrimidoneThe metabolism of Risedronate can be increased when combined with Primidone.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Risedronate.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Risedronate.
PuromycinPuromycin may increase the hypocalcemic activities of Risedronate.
RabeprazoleThe therapeutic efficacy of Risedronate can be decreased when used in combination with Rabeprazole.
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Risedronate.
RanitidineThe serum concentration of Risedronate can be increased when it is combined with Ranitidine.
RapacuroniumRisedronate may increase the neuromuscular blocking activities of Rapacuronium.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Risedronate.
RibostamycinRibostamycin may increase the hypocalcemic activities of Risedronate.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Risedronate.
Roxatidine acetateThe serum concentration of Risedronate can be increased when it is combined with Roxatidine acetate.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Risedronate.
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Risedronate.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Risedronate.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Risedronate.
SecobarbitalThe metabolism of Risedronate can be increased when combined with Secobarbital.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Risedronate.
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Risedronate.
SilodosinSilodosin may increase the hypotensive activities of Risedronate.
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Risedronate.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Risedronate.
SpectinomycinSpectinomycin may increase the hypocalcemic activities of Risedronate.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Risedronate.
StreptomycinStreptomycin may increase the hypocalcemic activities of Risedronate.
StreptozocinStreptozocin may increase the hypocalcemic activities of Risedronate.
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Risedronate.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Risedronate.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Risedronate.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Risedronate.
TAK-390MRThe therapeutic efficacy of Risedronate can be decreased when used in combination with TAK-390MR.
TamsulosinTamsulosin may increase the hypotensive activities of Risedronate.
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Risedronate.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Risedronate.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Risedronate.
TerazosinTerazosin may increase the hypotensive activities of Risedronate.
TerbinafineThe risk or severity of adverse effects can be increased when Terbinafine is combined with Risedronate.
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Risedronate.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Risedronate.
ThiamylalThe metabolism of Risedronate can be increased when combined with Thiamylal.
ThiopentalThe metabolism of Risedronate can be increased when combined with Thiopental.
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Risedronate.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Risedronate.
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronate.
TobramycinTobramycin may increase the hypocalcemic activities of Risedronate.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Risedronate.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Risedronate.
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Risedronate.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Risedronate.
TrimazosinTrimazosin may increase the hypotensive activities of Risedronate.
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Risedronate.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Risedronate.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Risedronate.
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Risedronate.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Risedronate.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Risedronate.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Risedronate.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Poly(a) rna binding
Specific Function:
Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, d...
Gene Name:
FDPS
Uniprot ID:
P14324
Molecular Weight:
48275.03 Da
References
  1. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G: Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41. [PubMed:10620343 ]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  3. Coxon FP, Ebetino FH, Mules EH, Seabra MC, McKenna CE, Rogers MJ: Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone. 2005 Sep;37(3):349-58. [PubMed:16006204 ]
  4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603 ]
  5. Ortiz-Gomez A, Jimenez C, Estevez AM, Carrero-Lerida J, Ruiz-Perez LM, Gonzalez-Pacanowska D: Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate. Eukaryot Cell. 2006 Jul;5(7):1057-64. [PubMed:16835450 ]
  6. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH: Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007 Nov;1117:209-57. [PubMed:18056045 ]
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
antagonist
References
  1. Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564 ]
  2. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Valenti MT, Giannini S, Donatelli L, Zanatta M, Bertoldo F, Sella S, Vilei MT, Ossi E, Realdi G, Lo Cascio V, Dalle Carbonare L: The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation. Arthritis Res Ther. 2010;12(4):R163. doi: 10.1186/ar3122. Epub 2010 Aug 25. [PubMed:20738860 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 03:38